[
    {
        "file_name": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_DevelopmentAgreement.txt",
        "perturbation": [
            {
                "type": "Ambiguities - In Text Contradiction",
                "original_text": "1.9 Commercially Reasonable Efforts means, with respect to the efforts to be used by a Party under this Agreement with respect to the Licensed Products, those efforts and resources normally used by a major pharmaceutical or a sufficiently financed biotechnology company for a product owned by it, or to which it has rights, which is of similar market potential at comparable stages of development, taking into account the competitiveness of the marketplace, the proprietary position of the product, the performance of other products that are of similar market potential and the likely timing of other product's entry into the market, the regulatory structure involved, the profitability of the applicable product, relevant Third Party intellectual property necessary to manufacture or Commercialize the Licensed Product and other relevant factors commonly considered in similar circumstances, including technical, legal, scientific or medical factors.",
                "changed_text": "1.9 Commercially Reasonable Efforts means, with respect to the efforts to be used by a Party under this Agreement with respect to the Licensed Products, those efforts and resources that a Party is capable of expending, but does not require a Party to take actions that are commercially detrimental. In determining whether such efforts are being made, the sole consideration should be based on financial return. This definition shall override any other definition of this term in any other agreement.",
                "explanation": "The original definition of 'Commercially Reasonable Efforts' describes a standard based on industry norms and multiple factors, including market potential and profitability. The modified definition narrows it to a party's capability and financial return, potentially allowing a party to avoid obligations if they are not financially beneficial, regardless of industry standards.",
                "location": "Section 1.9"
            },
            {
                "type": "Ambiguities - In Text Contradiction",
                "original_text": "1.39 Licensed Product means the finished dosage forms (including final packaging) of the biosimilars containing Ranibizumab which have been Developed and/or are being Developed by Bioeq to each of the Existing Reference Products ([***]). For clarity, Licensed Products include without limitation Vial Products and PFS Products, and shall extend to any New Products to the extent this Agreement is amended in accordance with Section 3.4",
                "changed_text": "1.39 Licensed Product means the finished dosage forms (including final packaging) of the biosimilars containing Ranibizumab which have been Developed and/or are being Developed by Bioeq to each of the Existing Reference Products ([***]). For clarity, Licensed Products include only Vial Products, and shall not extend to PFS Products, and shall not extend to any New Products.",
                "explanation": "The original definition includes Vial Products, PFS Products, and any New Products that extend in accordance with section 3.4. The changed definition limits Licensed Products to only Vial Products, and excludes any extension to PFS Products, and excludes any New Products. This means that some parts of the contract may refer to these other products as part of Licensed Products, while this definition explicitly excludes them.",
                "location": "Section 1.39"
            },
            {
                "type": "Ambiguities - In Text Contradiction",
                "original_text": "15.2.2 Termination by Bioeq for Underperformance. Subject to the second sentence of this Section 15.2.2, Bioeq may notify Licensee of its intent to terminate this Agreement anytime within thirty ([***]) days following the end of any [***] ([***]) month time period starting [***] ([***]) months after the First Commercial Sale of the first [***] Product in the Field in the Territory upon written notice to Licensee, if Licensee, with respect to its sales of Licensed Products in the Field in the Territory, has not achieved an average market share of at least [***] percent ([***]%) of the [***] (such market excluding for clarity in all cases [***]), calculated based on [***] in the Field in the Territory in the [***] ([***]) months prior to the end of such [***] ([***]) month time period (i.e., for example, in months [***] of the [***] after the First Commercial Sale of such [***] Product) (Minimum Market Share Requirement); upon Licensee's receipt of such notice from Bioeq, if Licensee does not achieve the Minimum Market Share Requirement, applied mutatis mutandis, during the subsequent [***] ([***]) months period following its receipt of such notice from Bioeq (Licensee Cure Period), Bioeq may terminate this Agreement upon written notice to Licensee; provided further, that the termination right described in this Section 15.2.2 shall apply only if [***], and provided further that such failure of Licensee to achieve the Minimum Market Share Requirement (i) is not due to any [***] (including [***]); (ii) not due to any [***] Bioeq's right to notify Licensee of its intent to terminate this Agreement in accordance with the first sentence of this Section 15.2.2 shall apply only until [***] ([***]) days after the [***] ([***]) anniversary of the First Commercial Sale of the first [***] Product in the Field in the Territory, after which Bioeq shall have no further rights under this Section 15.2.2.",
                "changed_text": "15.2.2 Termination by Bioeq for Underperformance. Bioeq may notify Licensee of its intent to terminate this Agreement at any time for any reason, with or without cause, provided that Bioeq provides 30 days written notice to Licensee. Bioeq may terminate this Agreement at its sole discretion.",
                "explanation": "Original terms states that Bioeq may terminate the contract only if the licensee does not achieve a percentage of a market share. This is limited to a certain period of time. The modified text states that Bioeq may terminate the contract at any time for any reason. Meaning the contract has conflicting information with the other parts of the document.",
                "location": "Section 15.2.2"
            }
        ]
    }
]